---
layout: post
title: "Prospective Grant of an Exclusive Patent License: Engineered Tumor Infiltrating Lymphocytes for Cancer Therapy"
date: 2026-02-05 19:08:35 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2021-03873
original_published: 2021-02-25 00:00:00 +0000
significance: 8.00
---

# Prospective Grant of an Exclusive Patent License: Engineered Tumor Infiltrating Lymphocytes for Cancer Therapy

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** February 25, 2021 00:00 UTC
**Document Number:** 2021-03873

## Summary

The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Iovance Biotherapeutics, Inc. ("Iovance"), headquartered in San Carlos, CA.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2021/02/25/2021-03873/prospective-grant-of-an-exclusive-patent-license-engineered-tumor-infiltrating-lymphocytes-for)
- API: https://www.federalregister.gov/api/v1/documents/2021-03873

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
